The company said it will use the funding to accelerate the development of an affordable sequencing test for metagenomic samples.
The firm plans to integrate its technology with a compatible microfluidic sample prep method developed by researchers at Columbia University.
SolveBio is continuing development of a cloud-based genetic variation analysis and visualization system called Variant Explorer.
The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.
The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.
The company aims to commercialize the platform and related services by late 2018.
The SBIR Phase 1 award will go toward developing a test using immuno-PCR technology to detect toxins in medical marijuana.
The company is working with the University of Florida Health Cancer Center to validate its RadTox QuantiDNA test as a monitor of cfDNA in patient plasma.
The company has received grant funding for diagnostic development projects, and is also seeking its first pharma service customers to provide nearer-term revenue.
The funding will go towards developing the PathMap companion diagnostic technology, based on the firm's SnapPath platform.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.